There is no clinical penalty for slower escalation
At the class level, both have a GI-dominant profile (nausea, vomiting, diarrhoea) that concentrates at dose escalation
For further information: DOI:10.1001/jamainternmed.2022.0338 Keywords: GLP-1 RA, Glucagon-like peptide-1 receptor agonists, biliary disease, Gallbladder disease, higher doses, Longer duration of GLP-1 RA, cholelithiasis, cholecystitis, GRADE framework, biliary cancer, JAMA Internal Medicine
Study Ties Diabetes, Weight Loss Drugs to Serious Digestive Issues Fact-Checked Editors carefully fact-check all Consumer Notice, LLC content for accuracy and quality
Can You Take Metformin and Ozempic Together